shares fell by more than 16% on Thursday after it cut its Covid-19 vaccine sales forecast for the year and missed earnings and revenue expectations for the third quarter.
By comparison, Pfizer has said it expects Covid vaccine sales of $36 billion this year and $29 billion in 2022. He said the company is working to ensure the vaccine is available in low-income countries by providing approximately 10% of its 2021 volume to them, and "significantly more" volume next year.
Hemos resumido esta noticia para que puedas leerla rápidamente. Si estás interesado en la noticia, puedes leer el texto completo aquí. Leer más: